Crizotinib has recently shown therapeutic efficacy in NSCLC patients carrying other rearrangements and alterations, including those involving ROS1 (c-ros oncogene 1), RET (rearranged during transfection), MET amplification and MET exon 14 deletion11, 12, 13, 14. Here, ROS1 is linked to non-small cell lung carcinoma.